[{"address1": "Level 10", "address2": "Tower 11 Avenue 5, No. 8 Jalan Kerinchi", "city": "Kuala Lumpur", "zip": "592000", "country": "Malaysia", "phone": "60 9 08517 7330", "website": "https://www.cyclacel.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Sing Ee Wong", "age": 43, "title": "Chairman, CEO & President", "yearBorn": 1981, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cu Seng Kiu", "age": 34, "title": "Executive Director, CFO & Secretary", "yearBorn": 1990, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gill  Christie", "age": 67, "title": "Director of Human Resources", "yearBorn": 1957, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Grace  Kim", "title": "Investor Relations Executive", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.6, "open": 1.56, "dayLow": 1.56, "dayHigh": 1.8184, "regularMarketPreviousClose": 1.6, "regularMarketOpen": 1.56, "regularMarketDayLow": 1.56, "regularMarketDayHigh": 1.8184, "payoutRatio": 0.0, "trailingPE": 0.5659722, "forwardPE": -0.8190955, "volume": 229081, "regularMarketVolume": 229081, "averageVolume": 198317, "averageVolume10days": 207800, "averageDailyVolume10Day": 207800, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 38727984, "fiftyTwoWeekLow": 1.36, "fiftyTwoWeekHigh": 41.12, "priceToSalesTrailing12Months": 2766.2847, "fiftyDayAverage": 3.5682, "twoHundredDayAverage": 8.30645, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 577421760, "profitMargins": 0.0, "sharesOutstanding": 23759500, "sharesShort": 30021, "sharesShortPriorMonth": 1726, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.0013, "heldPercentInsiders": 0.61492, "heldPercentInstitutions": 0.066360004, "shortRatio": 0.07, "shortPercentOfFloat": 0.003, "impliedSharesOutstanding": 13665400, "bookValue": 0.015, "priceToBook": 108.66667, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -8347000, "trailingEps": 2.88, "forwardEps": -1.99, "lastSplitFactor": "1:16", "lastSplitDate": 1747008000, "enterpriseToRevenue": 41244.414, "enterpriseToEbitda": -45.54, "52WeekChange": -0.9519458, "SandP52WeekChange": 0.1189177, "lastDividendValue": 0.15, "lastDividendDate": 1745884800, "quoteType": "EQUITY", "currentPrice": 1.63, "recommendationKey": "none", "totalCash": 3450000, "totalCashPerShare": 0.01, "ebitda": -12679500, "totalDebt": 9000, "quickRatio": 5.204, "currentRatio": 5.602, "totalRevenue": 14000, "debtToEquity": 0.294, "revenuePerShare": 0.0, "returnOnAssets": -1.6018, "returnOnEquity": -19.50234, "grossProfits": 14000, "freeCashflow": -13246125, "operatingCashflow": -10754000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -906.0714, "financialCurrency": "USD", "symbol": "CYCC", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Cyclacel Pharmaceuticals, Inc.", "longName": "Cyclacel Pharmaceuticals, Inc.", "postMarketChangePercent": -1.22699, "postMarketPrice": 1.61, "postMarketChange": -0.02, "regularMarketChange": 0.03, "regularMarketDayRange": "1.56 - 1.8184", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 198317, "fiftyTwoWeekLowChange": 0.26999998, "fiftyTwoWeekLowChangePercent": 0.19852939, "fiftyTwoWeekRange": "1.36 - 41.12", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1079447400000, "fiftyTwoWeekHighChange": -39.489998, "fiftyTwoWeekHighChangePercent": -0.9603599, "fiftyTwoWeekChangePercent": -95.19458, "dividendDate": 1746057600, "earningsTimestamp": 1747284600, "earningsTimestampStart": 1754996340, "earningsTimestampEnd": 1755518400, "earningsCallTimestampStart": 1723667400, "earningsCallTimestampEnd": 1723667400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 2.88, "epsForward": -1.99, "fiftyDayAverageChange": -1.9382001, "fiftyDayAverageChangePercent": -0.5431871, "twoHundredDayAverageChange": -6.67645, "corporateActions": [], "postMarketTime": 1748647713, "regularMarketTime": 1748635200, "exchange": "NCM", "messageBoardId": "finmb_125004", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.875, "regularMarketPrice": 1.63, "twoHundredDayAverageChangePercent": -0.8037669, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "displayName": "Cyclacel Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-05-31"}]